Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Structural determinants associated with risk of human developmental toxicity

Article Abstract:

A computer-automated algorithm that evaluates chemical structures may be capable of identifying chemicals that could be toxic to human fetuses. Researchers developed the MULTICASE (multiple computer-automated structure evaluation) algorithm to identify which of 60,000 chemicals in commercial use may be toxic to developing fetuses. MULTICASE identified 17 chemical structural features that could potentially be toxic to developing humans. The database and the predictive ability of MULTICASE had high internal and cross validity. Only 5% of the 60,000 commercial use chemicals have been actually evaluated.

Author: Mattison, Donald R., Ghanooni, Michael, Zhang, Ying P., Macina, Orest T., Rosenkranz, Herbert S., Klopman, Gilles
Publisher: Elsevier B.V.
Publication Name: American Journal of Obstetrics and Gynecology
Subject: Health
ISSN: 0002-9378
Year: 1997
Models, Toxicity testing, Toxicity tests

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Pregnancy outcome after gestational exposure to mebendazole: a prospective controlled cohort study

Article Abstract:

The antiparasitic drug mebendazole is probably safe to use in pregnant women with pinworm infections if used at the recommended dosage. This was the conclusion of researchers who analyzed data on 192 pregnant women from the Israeli Teratogen Information Service. All of the women had taken mebendazole during their first trimester. The rate of birth defects was no higher than in the general population.

Author: Diav-Citrin, Orna, Shechtman, Svetlana, Arnon, Judy, Lubart, Israela, Ornoy, Asher
Publisher: Elsevier B.V.
Publication Name: American Journal of Obstetrics and Gynecology
Subject: Health
ISSN: 0002-9378
Year: 2003
Mebendazole

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment

Article Abstract:

According to a registry developed by Glaxo Wellcome, acyclovir, lamotrigine, and sumatriptan do not increase the risk of birth defects. Acyclovir is an antiviral drug, lamotrigine is used to treat epilepsy and sumatriptan is used to treat migraine.

Author: Reiff-Eldridge, Robbin, Heffner, Cindy R., Ephross, Sara A., Tennis, Patricia S., White, Alice D., Andrews, Elizabeth B.
Publisher: Elsevier B.V.
Publication Name: American Journal of Obstetrics and Gynecology
Subject: Health
ISSN: 0002-9378
Year: 2000
Product information, Glaxo Wellcome PLC, Acyclovir, Lamotrigine, Sumatriptan

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Risk factors, Birth defects, Complications and side effects
Similar abstracts:
  • Abstracts: Longitudinal head growth in developmentally normal preterm infants. Catch-up growth during childhood among very low-birth-weight children
  • Abstracts: Septic shock in pregnancy associated with legionella pneumonia: case report. Ultrasonographic detection of ureteral jets in normal pregnancy
  • Abstracts: Macho culture prevents stress management. Hard-arm vibration research. Stress related work absence survey
  • Abstracts: Astral links. Blinded by the light: eye risk and the eclipse. Burn marks
  • Abstracts: Postmenopausal changes in serum cytokine levels and hormone replacement therapy. Cardiovascular responses of perimenopausal women to hormonal replacement therapy
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.